This Technology Stock Jumped 55% Following Q2 Results; Here Are 96 Biggest Movers From Yesterday
Gainers
Eargo, Inc. (NASDAQ: EAR) jumped 77.2% to close at $2.02. The FDA finalized rule enabling access to over-the-counter hearing aids.
ARK’s Cathie Wood Dumps More Twitter Stock, Buys $20M in Fate Therapeutics Stock
Cathie Wood-led Ark Investment Management has bought 628,060 shares of clinical-stage biopharmaceutical company Fate Therapeutics Inc. (NASDAQ: FATE) through two of the firm’s exchange-traded funds (ETF) valued at over $20 million based on Thursday’s closing pri
Cathie Wood Makes Massive Buy In Nvidia Stock: Here’s What You Should Know
Cathie Wood-led Ark Investment Management on Monday bought 366,982 shares of NVIDIA Corporation (NASDAQ: NVDA) valued at nearly $65.3 million, based on Monday’s closing price, via three of its exchange-traded funds.
Despite Durability Questions, BMO Upgraded This Natural-Killer Cell Therapy Oncology Stock
BMO Capital Market upgraded Fate Therapeutics Inc (NASDAQ:FATE) to Outperform from Market Perform. The analyst believes Fate’s iPSC platform is uniquely positioned…
BMO Capital Upgrades Fate Therapeutics to Outperform, Lowers Price Target to $47
BMO Capital analyst Etzer Darout upgrades Fate Therapeutics (NASDAQ:FATE) from Market Perform to Outperform and lowers the price target from $50 to $47.
Expert Ratings for Fate Therapeutics
Within the last quarter, Fate Therapeutics (NASDAQ:FATE) has observed the following analyst ratings:
BMO Capital Upgrades Fate Therapeutics to Outperform, Announces $47 Price Target
BMO Capital analyst Etzer Darout upgrades Fate Therapeutics (NASDAQ:FATE) from Market Perform to Outperform and announces $47 price target.